Snow, rapid revenue acceleration is just beginning for CTSO. If you are a chartist or invest solely on past performance, it easy to see a cautious approach. But, understanding the company's product, the growth of reorders, the expansion of distributors, the expansion of countries in which the product can be sold (now 40), and realizing that the gross margin on CytoSorb is exceptional at above 60%, a growth investor begins to realize how quickly this micro cap will become very profitable. What's more, remember when IBM PCs adopted the Windows operating system? IBM validated Windows, drew huge attention to it, and provided enormous cash flow for MSFT. It's okay to think of Fresenius in a similar way as a giant in the medical world. Starting in Q116, Fresenius starting featuring CytoSorb in its latest, most advanced machines. Two weeks ago, Terumo, a giant in cardiac surgery, is doing something similar. Remember, CytoSorb is a high-end disposable product. A new one is inserted into the machine for each use. CTSO already had a growing customer base prior to these partnership deals. My advice is to dig into the business from the ground up, the marketing organization, distributor partnerships, new customer growth, reorder growth, the expansion of medical indications for which the product is being used, and dozens of other relative points about the safety and efficacy of this product -- now with over 14,000 safe human uses and thousands of lives saved. It's also moving steadily toward FDA approval so it can be sold in the US, perhaps in 2018. This is a dynamic situation that deserves greater insight by investors than looking at one metric, IMO. Take a deeper look at CTSO.
